{"id":8513,"date":"2013-08-20T00:00:00","date_gmt":"2013-08-19T22:00:00","guid":{"rendered":"https:\/\/idibell.cat\/blog\/2013\/08\/20\/descobert-un-dels-mecanismes-que-afavoreix-lagressivitat-del-sarcoma-dewing\/"},"modified":"2021-11-18T10:49:58","modified_gmt":"2021-11-18T09:49:58","slug":"descobert-un-dels-mecanismes-que-afavoreix-lagressivitat-del-sarcoma-dewing","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2013\/08\/descobert-un-dels-mecanismes-que-afavoreix-lagressivitat-del-sarcoma-dewing\/","title":{"rendered":"Descobert un dels mecanismes que afavoreix l\u2019agressivitat del Sarcoma d\u2019Ewing"},"content":{"rendered":"

La caveolina-1 participa en la formaci\u00f3 de nous vasos sanguinis al voltant del tumor facilitant el seu creixement i la seva proliferaci\u00f3<\/strong><\/p>\n

La troballa obre la porta a la recerca de noves ter\u00e0pies contra aquest c\u00e0ncer infantil<\/strong><\/p>\n

Investigadors de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) liderats pel cap del grup de recerca en sarcomes, \u00d2scar Mart\u00ednez-Tirado, han descobert un dels mecanismes que desencadenen l\u2019angiog\u00e8nesi (formaci\u00f3 de nous vasos sanguinis) al voltant de les c\u00e8l\u00b7lules tumorals del Sarcoma d\u2019Ewing, un c\u00e0ncer infantil molt agressiu.<\/p>\n

Els resultats de l\u2019estudi, publicat a la revista PLoS ONE, obren la porta a una nova l\u00ednea de recerca de possibles ter\u00e0pies per aquest tumor.<\/p>\n

El sarcoma d\u2019Ewing \u00e9s el segon c\u00e0ncer d\u2019os m\u00e9s com\u00fa i afecta nens i joves. Actualment, si es diagnostica a temps i no presenta met\u00e0stasi, es pot curar en el 80% dels casos per\u00f2 entre el 25% i el 30% dels casos es diagnostiquen quan ja existeix met\u00e0stasi i la superviv\u00e8ncia baixa fins al 30%.<\/p>\n

Angiog\u00e8nesi i tumors s\u00f2lids<\/strong><\/p>\n

L\u2019angiog\u00e8nesi \u00e9s un proc\u00e9s clau en el creixement, proliferaci\u00f3 i migraci\u00f3 dels tumors s\u00f2lids. Les c\u00e8l\u00b7lules tumorals necessiten nous vasos sanguinis que els aportin l\u2019oxigen i els nutrients extra que necessiten per desenvolupar-se a un ritme tan r\u00e0pid.<\/p>\n

El grup d\u2019\u00d2scar Mart\u00ednez-Tirado ha descrit en diversos estudis les funcions de la prote\u00efna caveolina-1 en Sarcoma d\u2019Ewing: \u201cHem vist que t\u00e9 un paper tumorog\u00e8nic en aquest tipus de tumor, que participa en la resist\u00e8ncia a la quimioter\u00e0pia, que afavoreix la met\u00e0stasi i en aquest treball hem demostrat que juga un paper fonamental en el proc\u00e9s angiog\u00e8nic\u201d.<\/p>\n

Els investigadors van comprovar que, en l\u00ednees cel\u00b7lulars modificades gen\u00e8ticament per no expressar la caveolina-1, els tumors eren m\u00e9s petits, presentaven m\u00e9s necrosi i l\u2019\u00edndex de vascularitzaci\u00f3 era significativament m\u00e9s baix que en l\u00ednees amb caveolina-1. \u201cPer tant, la manca de caveolina-1 impedeix l\u2019angiog\u00e8nesi\u201d ha afirmat Mart\u00ednez-Tirado.<\/p>\n

L\u2019investigador ha explicat que tot i que la caveolina-1 sembla ser una possible diana terap\u00e8utica per a combatre el sarcoma d\u2019Ewing, la seva localitzaci\u00f3, la fa de molt dif\u00edcil acc\u00e9s: \u201cAix\u00ed que hem de buscar prote\u00efnes que s\u2019uneixen a la caveolina-1 i puguin adoptar aquest paper\u201d<\/p>\n

En aquest sentit, l\u2019estudi descriu com la caveolina-1 interacciona amb una altra prote\u00efna anomenada EphA2 activant una ruta de senyalitzaci\u00f3 que indueix l\u2019angiog\u00e8nesi, m\u00e9s concretament la migraci\u00f3 de les c\u00e8l\u00b7lules que han de formar els vasos, cap al tumor. Segons ha explicat Mart\u00ednez-Tirado \u201caquesta prote\u00efna \u00e9s un receptor de membrana que s\u00ed podria ser un bon candidat per ser diana terap\u00e8utica\u201d<\/p>\n

Possibles ter\u00e0pies de futur<\/strong>
\nAquesta troballa obre la porta a futures possibles ter\u00e0pies. \u201cAra hem d\u2019estudiar si a m\u00e9s d\u2019estar implicada en l\u2019angiog\u00e8nesi, la prote\u00efna EphA2 \u00e9s tumorog\u00e8nica per se<\/em>. Si ho \u00e9s, estem davant de la diana perfecta. La nostra idea de futur \u00e9s poder utilitzar aquesta prote\u00efna com a vehicle per alliberar dins les c\u00e8l\u00b7lules tumorals subst\u00e0ncies t\u00f2xiques\u201d ha explicat \u00d2scar Mart\u00ednez-Tirado.<\/p>\n

En aquest treball tamb\u00e9 han participat investigadors de l\u2019Hospital Vall d\u2019Hebron, de l\u2019Hospital Universitari de Salamanca i de l\u2019Hospital Sant Joan de D\u00e9u de Barcelona.<\/p>\n

 <\/p>\n

Refer\u00e8ncia de l\u2019article<\/strong>
\n<\/strong>S\u00e1inz-Jaspeado M., Huertas-Mart\u00ednez J., Lagares-Tena L., Liberal J.M., Mateo-Lozano S., de \u00c1lava E., de Torres C., Mora J., Garcia del Muro X. and Mart\u00ednez-Tirado O. EphA2-induced angiogenesis in Ewing sarcoma celles works through bGFG production and is dependent on caveolin-1. PLoS ONE. August 2013<\/p>\n","protected":false},"excerpt":{"rendered":"

La caveolina-1 participa en la formaci\u00f3 de nous vasos sanguinis al voltant del tumor facilitant el seu creixement i la seva proliferaci\u00f3 La troballa obre la porta a la recerca de noves ter\u00e0pies contra aquest c\u00e0ncer infantil Investigadors de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) liderats pel cap del grup de recerca en sarcomes, \u00d2scar […]<\/p>\n","protected":false},"author":6,"featured_media":19785,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[1,332,447,452,398],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-09 14:33:06","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/8513"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=8513"}],"version-history":[{"count":2,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/8513\/revisions"}],"predecessor-version":[{"id":19786,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/8513\/revisions\/19786"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/19785"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=8513"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=8513"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=8513"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}